“Dermatological Drugs market set to grow to $34bn by 2022” says Visiongain report

14 August 2018
Pharma

Visiongain’ has launched a new pharma report Dermatological Drugs Market Forecast 2018-2028: Psoriasis, Skin Infection, Acne, Dermatitis, Others

The dermatological drugs market is a specialist segment of the pharmaceutical market which over the last several years has been growing at a faster rate than the overall market. This has been due partly to the high growth potential of biological treatments for psoriasis. The development of new antibacterial drugs to address the problems of population ageing and drug-resistant strains of bacteria will also contribute to the overall market growth.

The lead analyst of the report commented "Visiongain notes that strong growth is expected in the skin structure infections (SSSI) sector of the dermatological drugs market. The increasing number of immunocompromised patients and the ageing population will contribute to the expansion expected in the segment of the market. We also expect growth to be driven by the development of new antibacterial drugs with better safety and efficacy profiles than existing antibiotics."

Leading companies featured in the report include AbbVie, Amgen, Bayer AG, Galderma (Nestle Skin Health S.A.), GlaxoSmithKline (GSK), Johnson & Johnson, LEO Pharma, Merck & Co, Inc., Novartis, Pfizer

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read